Pharma BD Deal Intelligence
GSK bought Phoenix for $253M to build a Latin America branded-generics beachhead, ran it into the ground, and sold it back to its original owners seven years later for roughly $150M — a clear value-destroying reversal.
Full analysis, sources & comparables →'By acquiring Phoenix, we will rapidly expand our presence in the fast growing Argentine market... Phoenix's broad portfolio and rich pipeline of branded…
GSK drives into Latin America's branded generics sector — Phoenix buy executes Witty's strategy of diversifying away from white-pill blockbusters into emerging…
Founder Hugo Sielecki repurchases Phoenix from GSK years after original sale — signaling the multinational's emerging-markets thesis underperformed…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
GSK acquired Argentine generics maker Laboratorios Phoenix for $253M to drive Latin America growth strategy.
GSK bought Phoenix for $253M to build a Latin America branded-generics beachhead, ran it into the ground, and sold it back to its original owners seven years later for roughly $150M — a clear value-destroying reversal.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| GlaxoSmithKline plc / Laboratorios Phoenix (this deal) | 2010 | $253M | 20 |
| GlaxoSmithKline plc / Theravance, Inc. | 2012 | $213M | 82 |
| GlaxoSmithKline plc / Tesaro Inc. | 2018 | $5.1B | 79 |
| GlaxoSmithKline plc / Pfizer Inc. (Consumer Healthcare Division) | 2018 | $12.7B | 76 |
| GlaxoSmithKline plc / Novartis Consumer Healthcare JV | 2018 | $13.0B | 74 |
| GlaxoSmithKline plc / ID Biomedical Corporation | 2005 | $1.4B | 64 |
| GlaxoSmithKline plc / Vir Biotechnology Inc. | 2020 | $595M | 51 |
← Browse all deals · How we score deals
More: 2010 deals · GlaxoSmithKline plc deals · Metabolic deals